Diagnostic firm AnchorDx Medical Co. Ltd. is now working with the Lung Cancer Initiative at Johnson & Johnson in a four-year lung cancer study that aims to enable early detection and diagnosis of the disease in China. The study takes place at six hospitals in the country and is expected to be completed in December 2024.

HONG KONG – Incheon, South Korea-based Celltrion Inc. will start manufacturing its COVID-19 treatment for clinical trials and commercial distribution, even though it’s only reached phase I. The phase I trials testing the in-house antiviral antibody treatment CT-P59 began on July 17, the same day the company received approval from Korea’s Ministry of Food and Drug Safety (MFDS) for its investigational new drug application on the back of positive preclinical results.

PARIS – Inheart SAS completed its first funding round of $4.2 million to improve cardiac arrhythmia treatment using medical imaging, artificial intelligence and digital simulation. This fund round was led by Elvia Partners SAS, a Parisian investment fund managed by Xavier Lazarus specializing in deep tech, and Aquitaine Science Transfer, a company accelerating technology transfer, from the University of Bordeaux.

The U.S. FDA announced July 18 that it has granted an emergency use authorization (EUA) to Quest Diagnostics Inc. for the company’s real-time, reverse transcriptase polymerase chain reaction test for the SARS-CoV-2 virus in a development that FDA commissioner Stephen Hahn described as “an important step forward.”

Commercial continuous glucose monitors (CGMs) require some access to a patient’s blood, typically through tiny needles embedded in a wearable patch sensor. But Movano Inc. is working to develop a CGM that is based on radio frequency technology to monitor glucose levels via a noninvasive, external wearable, likely in a form factor akin to a watch or a wrist-worn fitness wearable.

HONG KONG – Incheon, South Korea-based Celltrion Inc. will start manufacturing its COVID-19 treatment for clinical trials and commercial distribution, even though it’s only reached phase I.

The Xpert MTB/XDR test developed by the Foundation for Innovative New Diagnostics (FIND) and Cepheid Inc. quickly indicates whether a patient has a dangerous – and rapidly increasing – strain of multidrug resistant tuberculosis (TB). The new test enables clinicians to return results in 90 minutes and see immediately whether the pathogen would respond to standard first- or second-line therapies.